CMMB News and Press, Chemomab Therapeutics Ltd. From 04/12/23

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023 TEL AVIV, Israel , April ...

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023 PR Newswire TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and developme...

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology c...

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and develop...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: T. Schneider / Shutterstock.com Arrival (NASDAQ: ARVL ) stock is rising higher on Tuesday thanks to news of a $50 million new equity capital commitment. This comes from the electric vehicle (EV) company&#x...

Chemomab Therapeutics ( NASDAQ: CMMB ) stock rose ~17% on Tuesday after the company said that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application seeking to start a a phase 2 trial of CM-101 in adults with systemic sclerosis (SSc). ...

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis PR Newswire —ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for ...

Israeli biotech Chemomab Therapeutics ( NASDAQ: CMMB ) added ~35% pre-market Tuesday after announcing that its candidate for non-alcoholic steatohepatitis (NASH) CM-101 reached the primary endpoint in a Phase 2a trial. The 23-patient placebo-controlled trial was designed to evalua...

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients PR Newswire —CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments ...

Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis PR Newswire —Clean Safety Review Supports Addition of Higher Dose Cohort into the Trial — TEL AVIV, Israel , Dec. ...